Magnetic resonance imaging based radiomics for predicting pathogenetic features and survival in rectal cancer.

Abstract

Background: Prediction of pathologic features and outcome in patients with rectal cancer is challenging as a result of lack of a significant biomarker and heterogeneity between and within tumors. This study aims to evaluate the potential of Magnetic Resonance Imaging (MRI)-based radiomics in predicting key pathological features and long-term survival outcomes in patients.

Methods: A retrospective study was conducted on 510 rectal cancer patients treated between 2015 and 2019. The inclusion criteria required pre-therapeutic MRI performed on a Discovery MR750W 3.0T machine and known KRAS mutation status. Forty-seven patients met the criteria. MRI sequences included T1-weighted, T2-weighted fat-saturated (T2FS), high-resolution T2-weighted (T2HR), and diffusion-weighted imaging (DWI). Radiomic features were extracted using PyRadiomics, and machine learning models were developed using XGBoost and LightGBM classifiers. Feature selection was performed using Sequential Feature Selector (SFS) and Minimum Redundancy Feature Selection (mRMR).

Results: The model for KRAS mutation status achieved an Area Under the ROC curve (AUC) of 0.7475 (training) and 0.75 (testing). Lymph node invasion prediction had an AUC of 0.7892 (training) and 0.7984 (testing). Vascular invasion prediction yielded an AUC of 0.6989 (training) and 0.7143 (testing). The 5-year survival prediction model showed an AUC of 0.7848 (training) and 0.7750 (testing). Metastasis prediction achieved an AUC of 0.6627 (training) and 0.6857 (testing).

Conclusion: MRI-based radiomics demonstrates significant potential in predicting key pathological features and long-term survival outcomes in rectal cancer patients. Integrating multimodal imaging data and clinical information, along with automated segmentation techniques, could further enhance model accuracy and clinical utility.